NCT01407471View on ClinicalTrials.gov

Interest of Topical Spironolactone's Administration to Prevent Corticoid-induced Epidermal Atrophy

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Cutaneous Atrophy Due to Corticosteroids
Interventions
DRUG

Clobetasol + Spironolactone

One application 6 days a week during 4 weeks

DRUG

Clobetasol + Placebo

One application 6 days a week during 4 weeks

DRUG

Placebo + Spironolactone

One application 6 days a week during 7 weeks

DRUG

Placebo + Placebo

One application 6 days a week during 7 weeks

Trial Locations (1)

75877

Bichat Hospital, Paris

All Listed Sponsors
collaborator

Société de Dermatologie Française

OTHER

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT01407471 - Interest of Topical Spironolactone's Administration to Prevent Corticoid-induced Epidermal Atrophy | Biotech Hunter | Biotech Hunter